Abstract 2005: Quantitative screening of serum protein biomarkers by reversed phase protein serum arrays

Abstract

Abstract Protein biomarkers can be key indicators for cancer diagnosis, prediction, and selection of successful cancer treatments. Protein biomarkers can be identified by 2 methods: antibody arrays which profile protein expression levels from a patient's serum, or reversed phase protein arrays to measure single or limited sets of proteins from many patients’ sera. The reversed phase protein arrays have been widely used for detection of signaling molecules in cell lysates, however, this approach has been difficult to adapt to serum samples. Several years ago, we developed a sensitive method called the enhanced protein array to quantitatively measure serum protein levels from large numbers of patient samples. Here, we further refine the technology on several fronts: 1. simplifying the experimental procedure; 2. optimizing multiple parameters to make the assay more robust; 3. establishing a method for more accurate quantification. Using this technology, we quantitatively measured the protein expression levels of Nidogen-1 and CEACAM-1 from 164 serum samples from hepatocellular carcinoma (HCC) and equal number of control and found that both Nidogen-1 and CEACAM-1 expression levels are significantly increased in HCC patients. Our work reveals promise for using reversed phase protein serum arrays for biomarker discovery and validation. Citation Format: Zhizhou Kuang, Ruochun Huang, Shuhong Luo, Yun-Ru Chen, Zhiqiang Lv, Zhuo Zhang, Ruo-Pan Huang. Quantitative screening of serum protein biomarkers by reversed phase protein serum arrays. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2005. doi:10.1158/1538-7445.AM2015-2005